What you should know:
1. Omidria phenylephrine and ketorolac intraocular solution 1 percent/0.3 percent qualifies for separate payment retroactive to Oct. 1, 2020.
2. This is the first time Omidria is eligible under CMS’ payment policy for non-opioid pain management surgical drugs in the ASC.
3. Omidria is FDA-approved for use in cataract or lens replacement to prevent intraoperative pupil constriction and reduce postoperative ocular pain.
More articles on surgery centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
